CYTO logo

Altamira Therapeutics Ltd. (CYTO)

Profile

Full Name

Altamira Therapeutics Ltd.

Ticker

NASDAQ: CYTO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Bermuda

IPO

August 6, 2014

Indexes

Not included

Website

https://altamiratherapeutics.com

Employees

10

Key Details

Price

$0.30

Market Cap

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$0.00(-100.00% YoY)

Annual EPS

-$2.99(-108.57% YoY)

PE Ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $0.30
    CYTO price is $0.30

    30-Day Relative Volume

    0.00
    CYTO 30-day relative volume is 0.00

    Price Performance

    Price Most Recent Change

    -
    CYTO price change on Nov 25, 2025 is unknown

    Price YTD Change

    +171.49%
    CYTO price is up +171.49% since January 1st

    Price 1-Year Change

    -34.3%
    CYTO price is down -34.3% year-on-year

    Price 3-Year Change

    -99.71%
    CYTO price is down -99.71% over the past 3 years

    Price Range

    Price All-Time High

    $636800.00
    CYTO price is currently -100.00% below its historical high of $636800.00

    Price 3-Year Low

    $0.00
    CYTO price is currently >+9900.00% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market Cap

    $1.13M
    CYTO market cap is $1.13 million

    Market Cap 3-Year Change

    -81.26%
    CYTO market cap is down -81.26% over the past 3 years

    Market Cap All-Time High

    $249.28M
    CYTO market cap is currently -99.55% below its historical high of $249.28 million

    Market Cap Sector Percentile

    5.39%
    CYTO market cap is higher than 5.39% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    0%
    CYTO shares outstanding has remained unchanged year-on-year

    Shares Outstanding 3-Year Change

    +6358.97%
    CYTO shares outstanding is up +6358.97% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    4.77
    CYTO beta is 4.77

    200-day SMA

    $0.14
    CYTO price is currently +121.24% above its 200-day simple moving average

    50-day SMA

    $0.09
    CYTO price is currently +223.97% above its 50-day simple moving average

    14-Day RSI

    0.00
    CYTO 14-day relative strength index is 0.00

    Volume

    0.00
    CYTO 30-day relative volume is 0.00

    ATR

    $0.01
    CYTO average true range is $0.01

    10-day Historical Volatility

    1213.78%
    CYTO 10-day historical volatility is 1213.78%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $0.00
    CYTO annual revenue is $0.00

    Revenue Analysts Estimate

    -
    CYTO annual revenue consensus analysts' forecast is unknown

    Revenue 1-Year Change

    -100%
    CYTO annual revenue is down -100% year-on-year

    Revenue Sector Percentile

    28.27%
    CYTO annual revenue is higher than 28.27% of companies in Healthcare sector

    EPS

    EPS

    -$2.99
    CYTO annual earnings per share is -$2.99

    EPS Analysts Estimate

    -$1.17
    CYTO annual earnings per share is currently -155.56% lower than the consensus analysts' forecast

    EPS 1-Year Change

    -108.57%
    CYTO annual earnings per share is down -108.57% year-on-year

    EPS Sector Percentile

    30.59%
    CYTO annual earnings per share is higher than 30.59% of companies in Healthcare sector

    Profit

    Gross Profit

    -
    CYTO annual gross profit value is unknown

    Gross Margin

    -
    CYTO annual gross profit margin value is unknown

    Operating Profit

    -$6.92M
    CYTO annual operating income is -$6.92 million

    Operating Margin

    -
    CYTO annual operating profit margin value is unknown

    Net Income

    -$8.46M
    CYTO annual net profit is -$8.46 million

    Net Margin

    -
    CYTO annual net profit margin value is unknown

    Expenses

    Total Expenses

    $6.92M
    CYTO annual total expenses is $6.92 million

    Operating Expenses

    $6.92M
    CYTO annual total operating expenses is $6.92 million

    Cost Of Goods Sold

    -
    CYTO annual cost of goods sold value is unknown

    Selling, General & Administrative Expenses

    $3.07M
    CYTO annual SG&A is $3.07 million

    Depreciation & Amortization

    $127.05K
    CYTO annual D&A is $127.05 thousand

    Interest Expense

    $19.80K
    CYTO annual interest expense is $19.80 thousand

    Income Tax

    $0.00
    CYTO annual income tax is $0.00

    EBIT & EBITDA

    EBIT

    -$8.44M
    CYTO annual earnings before interest & taxes is -$8.44 million

    EBITDA

    -$7.49M
    CYTO annual EBITDA is -$7.49 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total Assets

    $8.65M
    CYTO annual total assets is $8.65 million

    Non Current Assets

    $7.11M
    CYTO annual long term assets is $7.11 million

    Current Assets

    $1.54M
    CYTO annual total current assets is $1.54 million

    Cash and Cash Equivalents

    $998.62K
    CYTO annual cash & cash equivalents is $998.62 thousand

    Accounts Receivable

    $0.00
    CYTO annual accounts receivable is $0.00

    Inventory

    $0.00
    CYTO annual inventory is $0.00

    Liabilities

    Total Liabilities

    $2.09M
    CYTO annual total liabilities is $2.09 million

    Long Term Liabilities

    $922.77K
    CYTO annual total long term liabilities is $922.77 thousand

    Current Liabilities

    $1.16M
    CYTO annual current liabilities is $1.16 million

    Accounts Payable

    $524.85K
    CYTO annual accounts payable is $524.85 thousand

    Debt

    Total Debt

    $361.05K
    CYTO annual total debt is $361.05 thousand

    Total Debt 1-Year Change

    +1504.68%
    CYTO annual total debt is up +1504.68% year-on-year

    Long Term Debt

    $238.69K
    CYTO annual long term debt is $238.69 thousand

    Short Term Debt

    -
    CYTO annual short term debt value is unknown

    Equity & Capital

    Shareholders Equity

    $6.57M
    CYTO annual stockholders equity is $6.57 million

    Book Value

    $1.94M
    CYTO annual book value is $1.94 million

    Retained Earnings

    -$3.03M
    CYTO annual retained earnings is -$3.03 million

    Working Capital

    $376.21K
    CYTO annual working capital is $376.21 thousand

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash From Operations

    -$6.11M
    CYTO annual cash from operations is -$6.11 million

    Cash From Operations 1-Year Change

    -894.88%
    CYTO annual cash from operations is down -894.88% year-on-year

    Cash From Investing

    -$115.34K
    CYTO annual cash from investing is -$115.34 thousand

    Cash From Investing 1-Year Change

    -4713.64%
    CYTO annual cash from investing is down -4713.64% year-on-year

    Cash From Financing

    $6.51M
    CYTO annual cash from financing is $6.51 million

    Cash From Financing 1-Year Change

    +446.38%
    CYTO annual cash from financing is up +446.38% year-on-year

    CAPEX

    CAPEX

    $103.09K
    CYTO annual capital expenditures is $103.09 thousand

    CAPEX 1-Year Change

    -
    CYTO annual capital expenditures 1-year change is unknown

    Free Cash Flow

    Free Cash Flow

    -$6.22M
    CYTO annual free cash flow is -$6.22 million

    Free Cash Flow 1-Year Change

    -911.66%
    CYTO annual free cash flow is down -911.66% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross Margin

    -
    CYTO annual gross profit margin value is unknown

    Operating Margin

    -
    CYTO annual operating profit margin value is unknown

    Net Margin

    -
    CYTO annual net profit margin value is unknown

    ROA & ROE

    ROA

    -97.75%
    CYTO annual return on assets is -97.75%

    ROE

    -128.83%
    CYTO annual return on equity is -128.83%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE Ratio

    -
    CYTO price to earnings ratio value is unknown

    PE Ratio Sector Percentile

    -
    CYTO price to earnings ratio is unknown

    PB Ratio

    PB Ratio

    0.58
    CYTO price to book ratio is 0.58

    PB Ratio Sector Percentile

    27.83%
    CYTO price to book ratio is higher than 27.83% of companies in Healthcare sector

    PS Ratio

    PS Ratio

    -
    CYTO price to sales ratio value is unknown

    PS Ratio Sector Percentile

    -
    CYTO price to sales ratio is unknown

    Enterprise value

    Enterprise Value

    $495.98K
    CYTO enterprise value is $495.98 thousand

    Enterprise Value Sector Percentile

    11.61%
    CYTO enterprise value is higher than 11.61% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -
    CYTO EV/EBITDA value is unknown

    EV/EBITDA Sector Percentile

    -
    CYTO EV/EBITDA is unknown

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current Ratio

    1.32
    CYTO annual current ratio is 1.32

    Quick Ratio

    1.32
    CYTO annual quick ratio is 1.32

    Leverage

    Debt To Equity

    0.05
    CYTO annual debt to equity ratio is 0.05

    Interest Coverage Ratio

    -426.09
    CYTO annual interest coverage ratio is -426.09

    Risk & Stability

    F-Score

    -
    CYTO piotroski f-score value is unknown

    Altman Z-Score

    -3.33
    CYTO altman z-score is -3.33

    Analyst ratings

    Recent major analysts updates

    No data about analysts updates

    Institutional Ownership

    Screeners with CYTO included

    Stocks cheaper than 1 dollar
    Stocks with high beta
    NASDAQ Dividend Calendar
    Stocks above SMA 50
    Stocks below analysts price target
    Healthcare sector
    All stocks
    NASDAQ Listed Companies
    Biotech Companies
    Best performing stocks YTD
    • What is the ticker symbol for Altamira Therapeutics Ltd.?
    • Does Altamira Therapeutics Ltd. pay dividends?
    • What sector is Altamira Therapeutics Ltd. in?
    • What industry is Altamira Therapeutics Ltd. in?
    • What country is Altamira Therapeutics Ltd. based in?
    • When did Altamira Therapeutics Ltd. go public?
    • Is Altamira Therapeutics Ltd. in the S&P 500?
    • Is Altamira Therapeutics Ltd. in the NASDAQ 100?
    • Is Altamira Therapeutics Ltd. in the Dow Jones?
    • When was Altamira Therapeutics Ltd.'s last earnings report?
    • When does Altamira Therapeutics Ltd. report earnings?

    What is the ticker symbol for Altamira Therapeutics Ltd.?

    The ticker symbol for Altamira Therapeutics Ltd. is NASDAQ:CYTO

    Does Altamira Therapeutics Ltd. pay dividends?

    No, Altamira Therapeutics Ltd. does not pay dividends

    What sector is Altamira Therapeutics Ltd. in?

    Altamira Therapeutics Ltd. is in the Healthcare sector

    What industry is Altamira Therapeutics Ltd. in?

    Altamira Therapeutics Ltd. is in the Biotechnology industry

    What country is Altamira Therapeutics Ltd. based in?

    Altamira Therapeutics Ltd. is headquartered in Bermuda

    When did Altamira Therapeutics Ltd. go public?

    Altamira Therapeutics Ltd.'s initial public offering (IPO) was on August 6, 2014

    Is Altamira Therapeutics Ltd. in the S&P 500?

    No, Altamira Therapeutics Ltd. is not included in the S&P 500 index

    Is Altamira Therapeutics Ltd. in the NASDAQ 100?

    No, Altamira Therapeutics Ltd. is not included in the NASDAQ 100 index

    Is Altamira Therapeutics Ltd. in the Dow Jones?

    No, Altamira Therapeutics Ltd. is not included in the Dow Jones index

    When was Altamira Therapeutics Ltd.'s last earnings report?

    Altamira Therapeutics Ltd.'s most recent earnings report was on September 8, 2021

    When does Altamira Therapeutics Ltd. report earnings?

    The date for Altamira Therapeutics Ltd.'s next earnings report has not been announced yet
    On this page